Skip to main content

Table 2 Subsequent second-line anticancer treatments in cohorts after sIPTW analysis

From: Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice

Treatments, n (%)

Palbociclib + letrozole (n = 839)

Letrozole alone (n = 698)

First-line treatment only*

448 (53.4)

233 (33.4)

Any second-line treatment received†

391 (46.6)

465 (66.6)

 CDK4/6 inhibitor

165 (42.2)

292 (62.9)

 Chemotherapy

100 (25.6)

44 (9.4)

 Endocrine therapy alone

64 (16.4)

96 (20.7)

 Other anticancer treatments

88 (22.5)

56 (12.0)

  1. CDK4/6 cyclin-dependent kinase 4/6, sIPTW stabilized inverse probability of treatment weighting
  2. *Includes patients who continued treatment, died, or were censored in the first-line setting
  3. †Patients could have received > 1 category of second-line treatment
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us